Aug. 19 at 11:14 AM
$CAPR CAPR is entering a window where nonāclinical forces (advocacy, politics, sentiment, FDA posture) matter almost as much as clinical data.
Thatās rare in biotech.
It means:
PPS is not purely dataādriven
PPS is not purely technical
PPS is not purely institutional
PPS is not purely fundamental
It is narrativeādriven, emotionādriven, and regulatorāsensitive.
This is why the Duchenne community mobilization matters.
ā Clean Summary ā Stated Plainly
Nearāterm, CAPR will be extremely volatile.
The Duchenne communityās mobilization increases the probability that FDA gives CAPRās amended BLA a real shot.
Lawsuits create noise but not fundamental damage.
PPS will swing violently on any regulatory or advocacy signal.
CAPR is not stable ā it is binary, emotional, and regulatorādriven.
